Gain Therapeutics (GANX) Competitors $1.66 -0.06 (-3.49%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GANX vs. HOOK, PASG, XFOR, HRTX, INZY, CRBU, TNYA, NBTX, KYTX, and SCPHShould you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include Hookipa Pharma (HOOK), Passage Bio (PASG), X4 Pharmaceuticals (XFOR), Heron Therapeutics (HRTX), Inozyme Pharma (INZY), Caribou Biosciences (CRBU), Tenaya Therapeutics (TNYA), Nanobiotix (NBTX), Kyverna Therapeutics (KYTX), and scPharmaceuticals (SCPH). These companies are all part of the "medical" sector. Gain Therapeutics vs. Hookipa Pharma Passage Bio X4 Pharmaceuticals Heron Therapeutics Inozyme Pharma Caribou Biosciences Tenaya Therapeutics Nanobiotix Kyverna Therapeutics scPharmaceuticals Gain Therapeutics (NASDAQ:GANX) and Hookipa Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings, media sentiment and community ranking. Is GANX or HOOK more profitable? Gain Therapeutics has a net margin of 0.00% compared to Hookipa Pharma's net margin of -86.74%. Hookipa Pharma's return on equity of -33.31% beat Gain Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gain TherapeuticsN/A -203.91% -128.05% Hookipa Pharma -86.74%-33.31%-21.65% Does the media refer more to GANX or HOOK? In the previous week, Hookipa Pharma had 3 more articles in the media than Gain Therapeutics. MarketBeat recorded 7 mentions for Hookipa Pharma and 4 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 0.44 beat Hookipa Pharma's score of -0.19 indicating that Gain Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hookipa Pharma 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer GANX or HOOK? Gain Therapeutics presently has a consensus target price of $7.33, indicating a potential upside of 341.77%. Hookipa Pharma has a consensus target price of $38.33, indicating a potential upside of 1,309.31%. Given Hookipa Pharma's higher possible upside, analysts clearly believe Hookipa Pharma is more favorable than Gain Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gain Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Hookipa Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, GANX or HOOK? Gain Therapeutics has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Comparatively, Hookipa Pharma has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Does the MarketBeat Community believe in GANX or HOOK? Hookipa Pharma received 60 more outperform votes than Gain Therapeutics when rated by MarketBeat users. Likewise, 70.54% of users gave Hookipa Pharma an outperform vote while only 68.89% of users gave Gain Therapeutics an outperform vote. CompanyUnderperformOutperformGain TherapeuticsOutperform Votes3168.89% Underperform Votes1431.11% Hookipa PharmaOutperform Votes9170.54% Underperform Votes3829.46% Which has better valuation & earnings, GANX or HOOK? Gain Therapeutics has higher earnings, but lower revenue than Hookipa Pharma. Gain Therapeutics is trading at a lower price-to-earnings ratio than Hookipa Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGain Therapeutics$50K880.46-$22.27M-$1.10-1.51Hookipa Pharma$20.13M1.63-$81.58M-$3.72-0.73 Do insiders & institutionals have more ownership in GANX or HOOK? 12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 63.9% of Hookipa Pharma shares are owned by institutional investors. 11.7% of Gain Therapeutics shares are owned by insiders. Comparatively, 3.3% of Hookipa Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryHookipa Pharma beats Gain Therapeutics on 10 of the 16 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GANX vs. The Competition Export to ExcelMetricGain TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.62M$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-1.514.8587.8613.46Price / Sales880.46374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / Book4.8810.216.946.30Net Income-$22.27M$153.61M$119.12M$225.93M7 Day Performance-4.87%-2.00%-1.84%-1.32%1 Month Performance-40.50%-7.47%-3.65%0.60%1 Year Performance-19.81%31.80%31.64%26.23% Gain Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GANXGain Therapeutics2.4867 of 5 stars$1.66-3.5%$7.33+341.8%-39.0%$45.62M$50,000.00-1.5120News CoverageGap DownHOOKHookipa Pharma2.4671 of 5 stars$2.72-2.5%$38.33+1,309.3%-46.4%$33.63M$20.13M-0.7356PASGPassage Bio2.9528 of 5 stars$0.51+6.2%$9.00+1,652.0%-19.0%$29.77MN/A0.00130XFORX4 Pharmaceuticals4.0062 of 5 stars$0.34-8.1%$2.88+744.6%-57.4%$62.76MN/A0.0080Analyst RevisionHRTXHeron Therapeutics3.9688 of 5 stars$1.12-5.9%$5.67+406.0%-13.8%$180.99M$127.04M0.00300Analyst DowngradeShort Interest ↓INZYInozyme Pharma1.2302 of 5 stars$2.79-0.7%$15.71+463.2%-28.5%$180.51MN/A0.0050CRBUCaribou Biosciences2.9415 of 5 stars$1.96-1.5%$11.25+474.0%-64.7%$180.20M$34.48M0.00100TNYATenaya Therapeutics3.9769 of 5 stars$2.22-2.2%$14.75+564.4%+18.4%$179.83MN/A0.00110Gap UpNBTXNanobiotix2.3432 of 5 stars$4.07+7.7%$11.50+182.7%-33.5%$178.16M$39.18M0.00100Positive NewsKYTXKyverna Therapeutics2.8357 of 5 stars$4.12+1.0%$25.71+524.1%N/A$176.14M$7.03M0.0096Analyst ForecastAnalyst RevisionGap UpSCPHscPharmaceuticals3.8122 of 5 stars$3.36-4.5%$15.00+346.4%-40.2%$176.14M$13.59M0.0030Analyst Revision Related Companies and Tools Related Companies Hookipa Pharma Alternatives Passage Bio Alternatives X4 Pharmaceuticals Alternatives Heron Therapeutics Alternatives Inozyme Pharma Alternatives Caribou Biosciences Alternatives Tenaya Therapeutics Alternatives Nanobiotix Alternatives Kyverna Therapeutics Alternatives scPharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GANX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
